(0.29%) 5 114.71 points
(0.39%) 38 390 points
(0.40%) 15 992 points
(-1.59%) $82.52
(4.84%) $2.02
(0.20%) $2 351.90
(0.17%) $27.58
(4.17%) $960.55
(-0.21%) $0.933
(-0.35%) $10.99
(-0.52%) $0.796
(1.69%) $93.42
Live Chart Being Loaded With Signals
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally...
Stats | |
---|---|
Dagens volum | 6.61M |
Gjennomsnittsvolum | 10.11M |
Markedsverdi | 15.91B |
EPS | $0 ( 2024-02-14 ) |
Neste inntjeningsdato | ( $0.510 ) 2024-05-08 |
Last Dividend | $0.0850 ( 2017-11-27 ) |
Next Dividend | $0 ( N/A ) |
P/E | -28.39 |
ATR14 | $0.0120 (0.08%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-05 | Kalif Eliyahu Sharon | Buy | 21 387 | Ordinary Shares |
2024-03-05 | Kalif Eliyahu Sharon | Buy | 52 320 | Ordinary Shares |
2024-03-06 | Kalif Eliyahu Sharon | Sell | 77 550 | Ordinary Shares |
2024-03-05 | Kalif Eliyahu Sharon | Sell | 21 387 | Restricted Share Units |
2024-03-05 | Kalif Eliyahu Sharon | Sell | 52 320 | Restricted Share Units |
INSIDER POWER |
---|
16.80 |
Last 98 transactions |
Buy: 2 305 980 | Sell: 1 612 593 |
Volum Korrelasjon
Teva Pharmaceutical Korrelasjon
10 Mest negative korrelasjoner |
---|
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Teva Pharmaceutical Korrelasjon - Valuta/Råvare
Teva Pharmaceutical Økonomi
Annual | 2023 |
Omsetning: | $15.85B |
Bruttogevinst: | $7.65B (48.25 %) |
EPS: | $-0.500 |
FY | 2023 |
Omsetning: | $15.85B |
Bruttogevinst: | $7.65B (48.25 %) |
EPS: | $-0.500 |
FY | 2022 |
Omsetning: | $14.93B |
Bruttogevinst: | $6.97B (46.72 %) |
EPS: | $-2.12 |
FY | 2021 |
Omsetning: | $15.88B |
Bruttogevinst: | $7.60B (47.83 %) |
EPS: | $0.380 |
Financial Reports:
No articles found.
Teva Pharmaceutical Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.00188 | 1987-02-23 |
Last Dividend | $0.0850 | 2017-11-27 |
Next Dividend | $0 | N/A |
Payout Date | 2017-12-12 | |
Next Payout Date | N/A | |
# dividends | 125 | -- |
Total Paid Out | $11.76 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.24 | -- |
Div. Sustainability Score | 4.54 | |
Div.Growth Potential Score | 0.418 | |
Div. Directional Score | 2.48 | -- |
Year | Amount | Yield |
---|---|---|
1987 | $0.00802 | 1.94% |
1988 | $0.00964 | 2.40% |
1989 | $0.00807 | 1.81% |
1990 | $0.00919 | 1.23% |
1991 | $0.00938 | 1.28% |
1992 | $0.0105 | 0.75% |
1993 | $0.0161 | 0.56% |
1994 | $0.0175 | 0.46% |
1995 | $0.0271 | 0.90% |
1996 | $0.0250 | 0.43% |
1997 | $0.0310 | 0.50% |
1998 | $0.0411 | 0.68% |
1999 | $0.0276 | 0.52% |
2000 | $0.0413 | 0.47% |
2001 | $0.0648 | 0.39% |
2002 | $0.0906 | 0.59% |
2003 | $0.163 | 0.83% |
2004 | $0.201 | 0.69% |
2005 | $0.269 | 0.92% |
2006 | $0.306 | 0.69% |
2007 | $0.385 | 1.23% |
2008 | $0.503 | 1.07% |
2009 | $0.605 | 1.42% |
2010 | $0.748 | 1.29% |
2011 | $0.901 | 1.71% |
2012 | $1.034 | 2.40% |
2013 | $1.278 | 3.44% |
2014 | $1.366 | 3.39% |
2015 | $1.360 | 2.42% |
2016 | $1.360 | 2.08% |
2017 | $0.850 | 2.27% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
LOMA | Dividend Knight | 2023-06-30 | Quarterly | 2 | 5.23% | 8.53 |
PVL | Dividend King | 2023-11-15 | Monthly | 14 | 9.37% | 8.50 |
NCV | Dividend Royal | 2024-02-09 | Monthly | 22 | 7.68% | 8.50 |
SBR | Dividend Royal | 2023-11-14 | Monthly | 38 | 7.74% | 8.50 |
MTR | Dividend Diamond | 2023-10-30 | Monthly | 39 | 10.10% | 8.50 |
PDI | Dividend Royal | 2023-11-10 | Monthly | 13 | 7.86% | 8.50 |
ZTR | Dividend King | 2024-02-09 | Monthly | 37 | 8.35% | 8.50 |
ORC | Dividend Royal | 2023-11-29 | Monthly | 12 | 9.23% | 8.50 |
KIO | Dividend Royal | 2023-12-14 | Monthly | 12 | 7.05% | 8.50 |
NCZ | Dividend Royal | 2024-02-09 | Monthly | 22 | 7.79% | 8.50 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.0353 | 1.500 | -0.706 | -1.058 | [0 - 0.5] |
returnOnAssetsTTM | -0.0129 | 1.200 | -0.429 | -0.514 | [0 - 0.3] |
returnOnEquityTTM | -0.0762 | 1.500 | -1.958 | -2.94 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 1.019 | 0.800 | 9.90 | 7.92 | [1 - 3] |
quickRatioTTM | 0.542 | 0.800 | -1.520 | -1.216 | [0.8 - 2.5] |
cashRatioTTM | 0.263 | 1.500 | 9.65 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.464 | -1.500 | 2.27 | -3.41 | [0 - 0.6] |
interestCoverageTTM | 0.914 | 1.000 | -0.773 | -0.773 | [3 - 30] |
operatingCashFlowPerShareTTM | 1.220 | 2.00 | 9.59 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.751 | 2.00 | 9.62 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 2.68 | -1.500 | 10.00 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.482 | 1.000 | 5.29 | 5.29 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0593 | 1.000 | -0.814 | -0.814 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.0679 | 1.000 | -0.734 | -0.734 | [0.2 - 2] |
assetTurnoverTTM | 0.364 | 0.800 | -0.904 | -0.723 | [0.5 - 2] |
Total Score | 4.54 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -27.69 | 1.000 | -2.90 | 0 | [1 - 100] |
returnOnEquityTTM | -0.0762 | 2.50 | -1.259 | -2.94 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.751 | 2.00 | 9.75 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 1.220 | 2.00 | 9.59 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.443 | 1.500 | -6.29 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0863 | 1.000 | -0.342 | 0 | [0.1 - 0.5] |
Total Score | 0.418 |
Teva Pharmaceutical
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.